Get a Sample Research Report @ https://www.databridgemarketresearch.com/reports/global-cystic-fibrosis-transmembrane-conductance-regulator-cftr-market
Growing awareness regarding this progressive genetic disease and the rising adoption of drug therapies are some of the major factors pushing the cystic fibrosis market growth. It has been witnessed that based on the route of administration, the oral segment is boosting the market for cystic fibrosis. Additionally, the approval of the first cystic fibrosis transmembrane conductance regulator (CFTR) modulator has changed the landscape of cystic fibrosis in the era of precision medicine.
Key Growth Drivers:
- Increased Cases of Cystic Fibrosis
As per the records of Cystic Fibrosis Patient Registry, more than 30,000 people are at present suffering from this condition in the U.S., while more than 70,000 people are claimed to be suffering from it globally. Additionally, around 1000 new cases of the disease are diagnosed each year. The rising occurrence of this disease is likely to increase the demand for combination treatments that will boost the industry progression in the coming years.
- Increasing Demand of Oral Segment
The oral segment is dominating the market for cystic fibrosis. The increased efficiency of orally administered medication in improving the quality of life and decreasing the intensity of symptoms is providing boost to the market growth of cystic fibrosis. In addition to this, the wide accessibility of oral medications such as Kalydeco, Ataluren, and N-acetylcysteine is also extending the development of the market. Furthermore, the increasing drift of patients towards oral treatments over intravenous therapy is resulting in the huge market growth. This boost the market growth.
The report outlines the involvement of key players, including:
Genentech Inc. (U.S.), Gilead Sciences, Inc. (U.S.), Novartis AG (Switzerland), AbbVie Inc. (U.S.), Pfizer Inc. (U.S.), GSK plc (U.K.), Johnson Johnson Private Limited (U.S.), Abbvie, Inc (U.S.), Mylan N.V. (U.S.), Pharmaxis Ltd (Australia), Vertex Pharmaceuticals Incorporated (U.S.)
Key Market Segmentation
Drug Class (CFTR Modulators, Mucolytics, Bronchodilators, Pancreatic Enzyme Supplements), Application (Congenital Bilateral Absence of the Vas Deferens, Cystic Fibrosis, Hereditary Pancreatitis, Others), Dosage (Liquids, Sprays, Injectables, Others), Route of Administration (Oral, Inhaled), End-Users (Hospitals, Homecare, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy)
Know More about This Premium Research Report @ https://www.databridgemarketresearch.com/reports/global-cystic-fibrosis-transmembrane-conductance-regulator-cftr-market
Browse More Reports:
https://www.databridgemarketresearch.com/reports/global-icu-devices-market
https://www.databridgemarketresearch.com/reports/global-ultramicrotome-market
https://www.databridgemarketresearch.com/reports/global-cryochambers-market
https://www.databridgemarketresearch.com/reports/global-monoclonal-antibodies-market
https://www.databridgemarketresearch.com/reports/global-tularemia-therapeutics-market
https://www.databridgemarketresearch.com/reports/global-pancreatitis-market
About Data Bridge Market Research, Private Ltd
Data Bridge Market Research is a multinational management consulting firm with offices in India and Canada. As an innovative and neoteric market analysis and advisory company with unmatched durability level and advanced approaches. We are committed to uncover the best consumer prospects and to foster useful knowledge for your company to succeed in the market.
Data Bridge Market Research has over 500 analysts working in different industries. We have catered more than 40% of the fortune 500 companies globally and have a network of more than 5000+ clientele around the globe.
Contact Us
US: +1 888 387 2818
UK: +44 208 089 1725
Hong Kong: +852 8192 7475
Email – corporatesales@databridgemarketresearch.com
